Spatial association of apoptosis-related gene expression and cellular death in clinical neuroblastoma

被引:35
作者
Hoehner, JC
Gestblom, C
Olsen, L
Pahlman, S
机构
[1] LUND UNIV, HOSP MAS, DEPT MED, WALLENBERG LAB, S-20502 MALMO, SWEDEN
[2] UNIV UPPSALA HOSP, DEPT PATHOL, S-75185 UPPSALA, SWEDEN
[3] UNIV UPPSALA HOSP, DEPT PEDIAT SURG, UPPSALA, SWEDEN
关键词
neuroblastoma; apoptosis; p53; Bcl-2; architecture; angiogenesis;
D O I
10.1038/bjc.1997.203
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Several unique features of neuroblastoma (NB), including the capacity for spontaneous regression and maturation to benign pathology, suggest that genes that regulate cellular proliferation, survival and differentiation may be involved in directing clinical tumour aggressiveness. The in situ expression of Bcl-2, Rb, p21, p53 and Bax proteins, as well as the proliferation marker proliferating cell nuclear antigen (PCNA) were examined immunocytochemically in a selection of 38 stage- and outcome-identified NE tumours. Apoptotic cells were identified morphologically and by a DNA fragmentation labelling technique (TUNEL). Although the tumour cell density of Bcl-2, p53, Bax, PCNA and TUNEL positivity correlated with patient survival, a spatially organized expression pattern was further recognized in stroma-poor differentiating tumours. Immature tumour cells adjacent to thin fibrovascular stroma are proliferating, as evidenced by PCNA positivity, and often express Bcl-2. At increasing distance from this fibrovascular stroma, intermediately differentiated tumour cells express Rb, while with more advanced differentiation, proliferation ceases and Bcl-2 immunoreactivity is lost. The most differentiated tumour cells, which often express p53, and occasionally p21 and Bax, lie adjacent to TUNEL-positive, morphologically apoptotic cells. This spatial organization favourable outcome NE tumours suggests that physiological regulation of differentiation and apoptosis may be involved in tumour regression.
引用
收藏
页码:1185 / 1194
页数:10
相关论文
共 85 条
[1]  
ALTSOPP TE, 1993, CELL, V73, P295
[2]  
ARENDS MJ, 1994, AM J PATHOL, V144, P1045
[3]  
Beckwith J B, 1968, J Pediatr Surg, V3, P106
[4]  
BECKWITH JB, 1963, AM J PATHOL, V43, P1089
[5]   REVISIONS OF THE INTERNATIONAL CRITERIA FOR NEUROBLASTOMA DIAGNOSIS, STAGING, AND RESPONSE TO TREATMENT [J].
BRODEUR, GM ;
PRITCHARD, J ;
BERTHOLD, F ;
CARLSEN, NLT ;
CASTEL, V ;
CASTLEBERRY, RP ;
DEBERNARDI, B ;
EVANS, AE ;
FAVROT, M ;
HEDBORG, F ;
KANEKO, M ;
KEMSHEAD, J ;
LAMPERT, F ;
LEE, REJ ;
LOOK, AT ;
PEARSON, ADJ ;
PHILIP, T ;
ROALD, B ;
SAWADA, T ;
SEEGER, RC ;
TSUCHIDA, Y ;
VOUTE, PA .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (08) :1466-1477
[6]   MOLECULAR-BASIS FOR HETEROGENEITY IN HUMAN NEUROBLASTOMAS [J].
BRODEUR, GM .
EUROPEAN JOURNAL OF CANCER, 1995, 31A (04) :505-510
[7]   THE RETINOBLASTOMA PROTEIN IS PHOSPHORYLATED DURING SPECIFIC PHASES OF THE CELL-CYCLE [J].
BUCHKOVICH, K ;
DUFFY, LA ;
HARLOW, E .
CELL, 1989, 58 (06) :1097-1105
[8]  
CASTLE VP, 1993, AM J PATHOL, V143, P1543
[9]   PHOSPHORYLATION OF THE RETINOBLASTOMA GENE-PRODUCT IS MODULATED DURING THE CELL-CYCLE AND CELLULAR-DIFFERENTIATION [J].
CHEN, PL ;
SCULLY, P ;
SHEW, JY ;
WANG, JYJ ;
LEE, WH .
CELL, 1989, 58 (06) :1193-1198
[10]   CRYSTAL-STRUCTURE OF A P53 TUMOR-SUPPRESSOR DNA COMPLEX - UNDERSTANDING TUMORIGENIC MUTATIONS [J].
CHO, YJ ;
GORINA, S ;
JEFFREY, PD ;
PAVLETICH, NP .
SCIENCE, 1994, 265 (5170) :346-355